Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study

Next Previous
Trial Profile

Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz; Lamivudine; Tenofovir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms DOLPHIN-1

    • Most Recent Events

    • 07 Mar 2018 Interim results presented at the 25th Conference on Retroviruses and Opportunistic Infections
    • 14 Mar 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 14 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top